Tags

Type your tag names separated by a space and hit enter

[Use of enalapril, an angiotensin-converting enzyme inhibitor, in pulmonary artery hypertension].
Arch Inst Cardiol Mex. 1986 Nov-Dec; 56(6):467-73.AI

Abstract

Enalapril (E) was used to treat 16 patients with pulmonary arterial hypertension, 6 primary and 10 secondary, 5 of the latter with congenital heart disease and 5 with chronic obstructive pulmonary disease. The average dose of E was 20 mg/day. All patients underwent pre and post-treatment cardiac catheterization with determination of pressures at: right atrial (RA), main pulmonary artery (MPA), pulmonary capillary wedge pressure (VCP) and systemic arterial (SA). Resistances forces were also measured as; total pulmonary (TPR), pulmonary arteriolar (PAR) and total systemic (TSR) as well as cardiac output (CO), and echo and electrocardiograms, chest x ray, stress test and respiratory function test. The functional class (NYHA) improved in all (p less than 0.001). The initial mean pressures were: RA 12.24 +/- 4.35; MPA 73.81 +/- 25.16; VCP 12 +/- 2.73 and SA 89 +/- 14; TPR 1477 +/- 761; PAR 1243 +/- 730 and TSR 1684 +/- 505.5; CO 4.5 +/- 1.29. The final values were: RA 9.66 +/- 2.46 (p less than 0.001); MPA 63.26 +/- 24.45 (p less than 0.001); VCP 11.33 +/- 2.38 (p = NS); SA 81 +/- 10 (p less than 0.001); TPR 1009.5 +/- 536.7 (p less than 0.001); PAR 829 +/- 511.5 (p less than 0.001); TSR 1309.6 +/- 296.3 (p less than 0.001); CO 5.2 +/- 1.44 (p less than 0.001). The average of minutes on treadmill was initially 8.2 +/- 2.45 and final 12.46 +/- 3.0 (p less than 0.001). It is concluded that enalapril is a useful drug in the treatment of pulmonary arterial hypertension of any etiology.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

spa

PubMed ID

3032121

Citation

Escudero, J, et al. "[Use of Enalapril, an Angiotensin-converting Enzyme Inhibitor, in Pulmonary Artery Hypertension]." Archivos Del Instituto De Cardiologia De Mexico, vol. 56, no. 6, 1986, pp. 467-73.
Escudero J, Navarro J, Padua A, et al. [Use of enalapril, an angiotensin-converting enzyme inhibitor, in pulmonary artery hypertension]. Arch Inst Cardiol Mex. 1986;56(6):467-73.
Escudero, J., Navarro, J., Padua, A., Betancourt, L., & Nava, G. (1986). [Use of enalapril, an angiotensin-converting enzyme inhibitor, in pulmonary artery hypertension]. Archivos Del Instituto De Cardiologia De Mexico, 56(6), 467-73.
Escudero J, et al. [Use of Enalapril, an Angiotensin-converting Enzyme Inhibitor, in Pulmonary Artery Hypertension]. Arch Inst Cardiol Mex. 1986 Nov-Dec;56(6):467-73. PubMed PMID: 3032121.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Use of enalapril, an angiotensin-converting enzyme inhibitor, in pulmonary artery hypertension]. AU - Escudero,J, AU - Navarro,J, AU - Padua,A, AU - Betancourt,L, AU - Nava,G, PY - 1986/11/1/pubmed PY - 1986/11/1/medline PY - 1986/11/1/entrez SP - 467 EP - 73 JF - Archivos del Instituto de Cardiologia de Mexico JO - Arch Inst Cardiol Mex VL - 56 IS - 6 N2 - Enalapril (E) was used to treat 16 patients with pulmonary arterial hypertension, 6 primary and 10 secondary, 5 of the latter with congenital heart disease and 5 with chronic obstructive pulmonary disease. The average dose of E was 20 mg/day. All patients underwent pre and post-treatment cardiac catheterization with determination of pressures at: right atrial (RA), main pulmonary artery (MPA), pulmonary capillary wedge pressure (VCP) and systemic arterial (SA). Resistances forces were also measured as; total pulmonary (TPR), pulmonary arteriolar (PAR) and total systemic (TSR) as well as cardiac output (CO), and echo and electrocardiograms, chest x ray, stress test and respiratory function test. The functional class (NYHA) improved in all (p less than 0.001). The initial mean pressures were: RA 12.24 +/- 4.35; MPA 73.81 +/- 25.16; VCP 12 +/- 2.73 and SA 89 +/- 14; TPR 1477 +/- 761; PAR 1243 +/- 730 and TSR 1684 +/- 505.5; CO 4.5 +/- 1.29. The final values were: RA 9.66 +/- 2.46 (p less than 0.001); MPA 63.26 +/- 24.45 (p less than 0.001); VCP 11.33 +/- 2.38 (p = NS); SA 81 +/- 10 (p less than 0.001); TPR 1009.5 +/- 536.7 (p less than 0.001); PAR 829 +/- 511.5 (p less than 0.001); TSR 1309.6 +/- 296.3 (p less than 0.001); CO 5.2 +/- 1.44 (p less than 0.001). The average of minutes on treadmill was initially 8.2 +/- 2.45 and final 12.46 +/- 3.0 (p less than 0.001). It is concluded that enalapril is a useful drug in the treatment of pulmonary arterial hypertension of any etiology. SN - 0020-3785 UR - https://www.unboundmedicine.com/medline/citation/3032121/[Use_of_enalapril_an_angiotensin_converting_enzyme_inhibitor_in_pulmonary_artery_hypertension]_ L2 - https://www.diseaseinfosearch.org/result/6088 DB - PRIME DP - Unbound Medicine ER -